Format

Send to

Choose Destination
Cancer Immunol Immunother. 2018 Jul 12. doi: 10.1007/s00262-018-2200-6. [Epub ahead of print]

Interactions among myeloid regulatory cells in cancer.

Author information

1
Skin Cancer Unit (G300), German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany. V.Umansky@dkfz-heidelberg.de.
2
Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht Karl University of Heidelberg, Mannheim, Germany. V.Umansky@dkfz-heidelberg.de.
3
Radiotherapy and OncoImmunology Laboratory, Department of Radiation Oncology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.
4
Department of Clinical Immunology, Institute of Paediatrics, Jagiellonian University Medical College, Kraków, Poland.
5
Department of Otorhinolaryngology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
6
Lab of Cellular and Molecular Immunology, Vrije Universiteit Brussel, Brussels, Belgium.
7
Myeloid Cell Immunology Lab, VIB Center for Inflammation Research, Brussels, Belgium.
8
Skin Cancer Unit (G300), German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany.
9
Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht Karl University of Heidelberg, Mannheim, Germany.
10
Laboratory for Experimental Hematology and Stem Cells, Institute for Medical Research, University of Belgrade, Belgrade, Republic of Serbia.
11
Department of Hematology, School of Medicine, University of Crete, Heraklion, Greece.
12
Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.
13
Department of Molecular Oncology, Institute for Medical Research, University of Belgrade, Belgrade, Republic of Serbia.
14
Centro Integrativo de Biología y Química Aplicada (CIBQA), Universidad Bernardo O'Higgins, Santiago, Chile.
15
Faculty of Medicine, Institute of Molecular Medicine (IMM)-João Lobo Antunes, University of Lisbon, Lisbon, Portugal.
16
Institute of Pulmonary Medicine, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.

Abstract

Mounting evidence has accumulated on the critical role of the different myeloid cells in the regulation of the cancerous process, and in particular in the modulation of the immune reaction to cancer. Myeloid cells are a major component of host cells infiltrating tumors, interacting with each other, with tumor cells and other stromal cells, and demonstrating a prominent plasticity. We describe here various myeloid regulatory cells (MRCs) in mice and human as well as their relevant therapeutic targets. We first address the role of the monocytes and macrophages that can contribute to angiogenesis, immunosuppression and metastatic dissemination. Next, we discuss the differential role of neutrophil subsets in tumor development, enhancing the dual and sometimes contradicting role of these cells. A heterogeneous population of immature myeloid cells, MDSCs, was shown to be generated and accumulated during tumor progression as well as to be an important player in cancer-related immune suppression. Lastly, we discuss the role of myeloid DCs, which can either contribute to effective anti-tumor responses or play a more regulatory role. We believe that MRCs play a critical role in cancer-related immune regulation and suggest that future anti-cancer therapies will focus on these abundant cells.

KEYWORDS:

Dendritic cells; Macrophages; Mye-EUNITER; Myeloid regulatory cells; Myeloid-derived suppressor cells; Neutrophils

PMID:
30003321
DOI:
10.1007/s00262-018-2200-6

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center